Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.
The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023.
PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | 0 Increased by +100% | -0.23 Increased by +100% |
| Sep 21, 23 | 0 Decreased by -100% | -0.22 Increased by +100% |
| May 9, 23 | 0 Decreased by N/A% | -0.21 Increased by +100% |
| Mar 22, 23 | 0 Increased by +100% | -0.19 Increased by +100% |
| Nov 21, 22 | -0.35 Increased by +44.5% | -0.35 Decreased by -0.77% |
| Sep 12, 22 | 0.3 Increased by +138.43% | -0.37 Increased by +179.65% |
| May 12, 22 | 0 Increased by +100% | -0.37 Increased by +100% |
| Mar 11, 22 | -0.39 Increased by +69.86% | -0.39 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -5.69 M Decreased by -10.72% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | N/A Decreased by N/A% | N/A Decreased by -100% | - - |
| Mar 31, 23 | N/A Decreased by N/A% | N/A Increased by +100% | - - |
| Dec 31, 22 | 0 Decreased by N/A% | 5.93 M Increased by +148.6% | Increased by +N/A% - |
| Sep 30, 22 | 0 Decreased by N/A% | -5.14 M Increased by +62.3% | Decreased by N/A% - |
| Jun 30, 22 | 0 Decreased by N/A% | 10.89 M Increased by +168.01% | Increased by +N/A% - |
| Mar 31, 22 | N/A Decreased by N/A% | -11.91 M Increased by +0.28% | - - |
| Dec 31, 21 | N/A Decreased by N/A% | -12.21 M Increased by +38.15% | - - |